Syncopation Life Sciences is advancing a new generation of adoptive cell therapies for cancers, with a new focused emphasis on addressing primary mechanisms of resistance to Chimeric Antigen Receptor T cell (CAR-T) therapies. Despite advances, approximately half of all patients treated with CAR-T therapies relapse. New and better treatments are needed.
By changing the beat with new engineering technologies, our founders and scientists are uncovering and addressing important mechanisms of resistance to make adoptive cell therapies better – much better. With our deep expertise in the design of CAR-T therapies combined with our proprietary insights and platforms, Syncopation is developing an exciting pipeline of programs with best-in-class potential to improve outcomes for cancer patients.